PMID- 36877884
OWN - NLM
STAT- MEDLINE
DCOM- 20230308
LR  - 20230308
IS  - 1545-9616 (Print)
IS  - 1545-9616 (Linking)
VI  - 22
IP  - 3
DP  - 2023 Mar 1
TI  - Breaking the Frustrating Cycle of Topical Steroids in Psoriasis: A Review of a 
      Novel Vehicle for Fixed-Dose Combination Halobetasol Propionate/Tazarotene.
PG  - 247-251
LID - 10.36849/JDD.7399 [doi]
AB  - Topical therapies are commonly used to treat psoriasis, either as monotherapy for 
      milder disease or as adjuncts to systemic and biologic drugs. Topical steroids 
      and tazarotene are both options for topical psoriasis treatment, but as 
      monotherapies, they are associated with adverse events (AEs) that make adherence 
      to prescribed treatment challenging. In addition, the topical vehicles may have 
      an unappealing appearance or texture that proves impractical for patients. 
      Consequently, patients may not use treatments as prescribed. This noncompliance 
      can lead to a frustrating cycle of treatment, discontinuation, and retreatment 
      without achieving treatment goals. Psoriasis is a chronic disease; thus, topical 
      treatment options are needed that address these barriers to use and promote 
      long-term adherence, making satisfactory improvement of psoriasis more 
      attainable. In this review, we discuss patient preferences for topical therapies 
      with vehicles that are moisturizing, nongreasy, and quickly absorbed. We then 
      introduce the vehicle formulation of fixed-dose combination halobetasol 
      propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion, which has a unique matrix 
      mesh formulation that enhances uniform absorption, allows for efficient drug 
      delivery, and aligns with patient preferences. In addition to vehicle benefits, 
      the combination of HP and TAZ has been shown to minimize AEs seen with either 
      monotherapy. In clinical trials, HP/TAZ was efficacious and associated with a low 
      rate of AEs with long-term use. This evidence supports the use of HP/TAZ as a 
      topical treatment for patients with psoriasis facing challenges adhering to 
      prescribed treatments and looking to break the cycle of unsatisfactory treatment 
      outcomes. J Drugs Dermatol. 2023;22(3):247-251. doi:10.36849/JDD.7399.
FAU - Kircik, Leon
AU  - Kircik L
FAU - Bhatia, Neal
AU  - Bhatia N
FAU - Lain, Edward
AU  - Lain E
FAU - Jacobson, Abby
AU  - Jacobson A
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Drugs Dermatol
JT  - Journal of drugs in dermatology : JDD
JID - 101160020
RN  - 81BDR9Y8PS (tazarotene)
RN  - 9P6159HM7T (halobetasol)
RN  - 0 (Propionates)
RN  - 0 (Steroids)
RN  - 0 (Excipients)
SB  - IM
MH  - Humans
MH  - *Propionates
MH  - Steroids
MH  - Excipients
MH  - *Psoriasis/diagnosis/drug therapy
EDAT- 2023/03/07 06:00
MHDA- 2023/03/09 06:00
CRDT- 2023/03/06 15:50
PHST- 2023/03/06 15:50 [entrez]
PHST- 2023/03/07 06:00 [pubmed]
PHST- 2023/03/09 06:00 [medline]
AID - S1545961623P0247X [pii]
AID - 10.36849/JDD.7399 [doi]
PST - ppublish
SO  - J Drugs Dermatol. 2023 Mar 1;22(3):247-251. doi: 10.36849/JDD.7399.